When speaking to public audiences, palliative care advocates often reach for personal experiences of great meaning and significance in their own lives, and often distill those experiences to a key message. However, this approach may not be the most effective way to engage a public audience whose closest experience with palliative care is based on social media or third-hand stories. Research demonstrates that the lay public often starts with inaccurate assumptions about palliative care, including that it is only for people at end of life. These misunderstandings can lead people with serious illness to decline palliative care services that are backed by evidence and demonstrate real benefit. This phenomenon of "declines based on inaccurate assumptions" is widely seen in clinical practice and palliative care demonstration projects. Public messaging is an evidence-based approach to engage more effectively with the public when doing outreach for palliative care. The 10 tips provided are based on a multiyear and multiorganizational project focused on improving the messaging of palliative care for the public. As palliative care services are increasingly expanded and integrated into health systems, public messaging can provide a new approach for building partnerships with the public by offering messages that consistently meet their needs based on their current perceptions. Incorporating public-informed messaging strategies could enable palliative care clinicians and advocates to address the lay public with greater confidence and clarity about how palliative care can serve them, their families, and their communities.

2023-02-01·Journal of palliative medicine

"Palliative Care Is the Only Medical Field That I Feel Like I'm Treated As a Person, Not As a Black Person": A Mixed-Methods Study of Minoritized Patient Experiences with Palliative Care.

Article

作者: Bandini, Julia I ; Messan Setodji, Claude ; Schulson, Lucy B ; Ast, Katherine ; Ahluwalia, Sangeeta C ; Williams, Jhacova

Background: Racial and ethnic disparities are well-documented in health care but generally understudied in palliative care. Objective: The goal of this mixed-methods study was to examine differences in patient experiences by race/ethnicity in palliative care and to qualitatively explore minoritized patient experiences with care for a serious illness. The data for this study were collected as part of a larger national effort to develop quality measures for outpatient palliative care. Setting/Subjects: Patients receiving outpatient palliative care (n = 153 Black patients and 2215 White patients) from 44 palliative care programs across the United States completed the survey; 14 patients and family caregivers who identified as racial/ethnic minorities participated in an in-depth qualitative interview. Measurements: We measured patients' experiences of (1) feeling heard and understood by their palliative care provider and team and (2) receiving desired help for pain using items developed from the larger quality measures project. We also conducted in-depth interviews with 14 patients and family caregivers to understand their experiences of palliative or hospice care to provide additional insight and understand nuances around minoritized patient experiences with palliative care. Results: Survey responses demonstrated that a similar proportion of Black patients and White patients (62.9% vs. 69.3%, p = 0.104) responded "completely true" to feeling heard and understood by their provider and team. Fewer Black patients than White patients felt that their provider understood what was important to them (53.3% vs. 63.9%, p = 0.009). The majority of Black patients and White patients (78.7% vs. 79.1%, p = 0.33) felt that they had received as much help for their pain as they wanted. Interviews with patient and family caregivers revealed positive experiences with palliative care but demonstrated experiences of discrimination in health care before referral to palliative care. Conclusion: Future work is needed to understand nuances around minoritized patient experiences with palliative care and receiving pain and symptom management.

2022-07-01·Journal of Palliative Medicine3区 · 医学

Experiences with Telehealth for Outpatient Palliative Care: Findings from a Mixed-Methods Study of Patients and Providers across the United States

3区 · 医学

Article

作者: Ast, Katherine ; Farmer, Carrie ; Mistler, Brian ; Fratkin, Michael ; Ahluwalia, Sangeeta C. ; Bandini, Julia I. ; Scherling, Adam

Background: The COVID-19 pandemic introduced a rapid adoption and scale-up of telehealth for palliative care services in the United Sates. Objectives: To examine and compare in-person versus telehealth experience among outpatient palliative care programs and patients. Design: Mixed-methods study (1) comparing patient experience survey data received between September 2020 and February 2021 from patients who received only in-person care versus those who received only telehealth and (2) qualitative interviews with outpatient palliative care providers. Data for this study were collected as part of a larger effort to develop quality measures for outpatient palliative care in the United States. Setting/Subjects: Outpatient palliative care patients and programs. Measurements: We measured patients' experiences of "feeling heard and understood" by their palliative care provider and team and their overall rating of their provider and team. We also conducted in-depth semistructured interviews with 47 palliative care providers across 25 outpatient palliative care programs. Results: Of 1753 patient experience surveys, 26% reflected telehealth only versus 74% in-person only. Patients in both groups reported highly positive experiences; there were no differences in "feeling heard and understood" or the overall ratings of the provider and team between the telehealth-only and in-person-only groups. Palliative care program leaders described the benefits and challenges of telehealth, including increased efficiency, the ability to incorporate family members, and challenges conducting a physical examination. Conclusion: Data from this study provide preliminary evidence of overall positive experiences of telehealth for outpatient palliative care among patients and providers; future research is needed to examine the sustainability of telehealth for palliative care.

项与 American Academy of Hospice & Palliative Medicine 相关的新闻（医药）

2024-04-09

·PRNewswire

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

Sales double in the USA, order intake increases by over 150 percent More than 50 percent increase in order intake in EMEA Business Area Technology & Services' sales grow by almost 25 percent Further improvement in profitability Exyte CEO Büchele: "Our follow-the-client strategy is paying off. We benefit in Europe and the USA from extensive investments in high-tech facilities." STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023. Last year the company was able to significantly increase its sales and order intake in both regions. Continue Reading Exyte, a global leader for high-tech facilities, shows strong growth in Europe and the USA (PRNewsfoto/Exyte) "Our follow-the-client strategy is paying off. We benefit in Europe and the USA from extensive investments in high-tech facilities," says Exyte CEO Dr. Wolfgang Büchele. Both regions will continue to be significant drivers of Exyte's business development in the current year and beyond. Fiscal Year 2023: Regionally diverging development Last year, Exyte achieved sales of €7.1 billion. Compared to the record sales in 2022, sales decreased by 4.7%. The reason for the slight decrease in sales is the completion of mega-projects, especially in Asia. New mega projects in EMEA and the USA are still in the ramp-up phase. The sales from these projects will only start to increase in future quarters. An additional factor is the delayed investment plans of clients. Companies, especially in the semiconductor sector, have postponed some projects. Reasons include increased financing costs and delays in government subsidies in some regions. These circumstances also impacted the order intake in 2023, which was approximately €7.2 billion. Exyte was awarded with several key projects all over the world in all three business segments in 2023. "This shows that Exyte's strong emphasis on megatrend-driven industries and our customer-centric strategy places us in a favourable position to maintain our growth ambitions. We are well positioned in growth markets globally," Büchele continues. Positive development of the financial result Despite the stagnation in sales development, Exyte continued to improve its profitability with an adjusted EBITDA of €484 million (2022: €460 million) and an adjusted EBIT of €435 million (2022: €416 million). The adjusted EBITDA margin was 6.9% (2022: 6.2%), while the adjusted EBIT margin reached 6.2% (2022: 5.6%). "Regardless of the temporarily adverse sales development, Exyte's short-, medium-, and long-term perspectives remain positive. Whether it's semiconductors, battery cells, biotechnology and pharmaceuticals, or data centers, customers in our target industries continue to invest in expanding their capacities", says Büchele. Financial year 2024: Increase in sales expected For 2024 Exyte sales are expected to increase again, driven by an increased order intake. All GBUs will contribute to this growth. Büchele says: "Our leading market position and our high order backlog of 6.7 billion euros at the end of 2023 enable us to resume our growth trajectory. We remain committed to our goal of achieving ten billion euros in sales by latest 2027 as part of our 'Pathway to Ten'. The profitability development will be impacted by the regional shift in business." Following the sales development, Exyte anticipates an absolute increase in adjusted EBIT for 2024, with a slightly declining adjusted EBIT margin compared to the fiscal year 2023. Growth Markets: Regional shift towards Europe and the USA Exyte sees a regional shift in its business development. The share of Asia is declining, while order intake and sales are increasing significantly in Europe and the USA. Especially clients of the Advanced Technology Facilities business segment benefit from subsidies for the semiconductor and battery cell industries in Western countries. While semiconductor factories have been built mostly in Asia in recent years, many large-scale projects are currently being developed or are already being implemented in the USA and Europe. "As a result, the regional distribution of sales will change in the coming years. In both Europe and the USA, we are expanding our organization to execute our clients' planned mega-projects," says Exyte board member Mark Garvey. Expansion of Technology & Services: Rising demand for products and services Exyte is also investing in expanding its production capacities in Europe and the USA to capitalize on the investment boom in the semiconductor industry. Among others, sites for offsite manufacturing have been established in Czech Republic and the USA. In Boise, Idaho, Exyte is expanding the production capacities of several product lines in the Business Area Technology & Services. Büchele explains: "We are establishing a strategic network of production and offsite manufacturing sites across Europe and the USA to increase the speed of project implementation for our clients." In the Czech Republic, Exyte increased its production capacities by expanding two existing locations and opening a third one. The products produced there are primarily used in the construction of semiconductor facilities in Europe. With strategic acquisitions, Exyte advances its strategy of vertical integration. This foresees strengthening the Technology & Services business area in the area of mission-critical equipment and installation services. Last year Exyte acquired Intega GmbH, a specialist in high-purity media supply systems. Exyte also recently completed the acquisition of CollabraTech Solutions, a US specialist in the design and production of distribution systems and contract manufacturing services . Regional expansion and business opportunities in Southeast Asia Despite the promising prospects in the USA and Europe, Exyte will continue to seize opportunities in Asia, especially in the biopharma and life sciences as well as data center sectors. In all of its three business segments, the company has recently successfully executed projects for international blue-chip customers, including chip factories for American, Asian, and German semiconductor manufacturers. Exyte intends to leverage its existing expertise in other markets as well. To this end, Exyte has entered into a strategic collaboration agreement with the Japanese company JGC Corporation . Both companies will explore the joint business development and execution of EPC projects, collaboratively expanding the business fields of high-tech facility projects in Southeast Asian emerging countries, namely Indonesia, Philippines, Vietnam, and Thailand. Global workforce: Continued need for technical experts To enable the expected growth, Exyte continues to onboard a high number of new employees, especially engineers, construction managers and project managers. As of December 31, 2023, Exyte employed 9,740 employees (Full Time Equivalent) worldwide. The global workforce has increased by 9% compared to the previous year. By 2027, Exyte expects to have 15,000 employees. Fiscal year 2023: Business performance across regions In AMER the order intake rose by more than 150% to €2.4 billion (2022: €961 million). Sales almost doubled and reached €1.1 billion (2022: €560 million). The APAC region's sales decreased by around 24% to €3.2 billion year-on-year (2022: €4.2 billion), whereas the order intake reached €1.2 billion (2022: €4.1 billion). With €2.1 billion (2022: €2.1 billion) EMEA contributed approximately 28% of total sales in 2023. Order intake amounted to €2.8 billion (2022: €1.8 billion), an increase of around 53%. Fiscal year 2023: Business performance across Global Business Units Advanced Technology Facilities: Driver of digitalization and electromobility With sales of €6.0 billion (2022: €6.4 billion), the business segment Advanced Technology Facilities contributed 85% of total group sales. Exyte anticipates a consistent increase of semiconductor and battery cell manufacturing due to the continuous rise in demand for these products. Major investments in both industries are also driven by financial support from governments, e.g., the European Chips Act and the US CHIPS and Science Act as well as the Inflation Reduction Act. In Europe, Exyte meanwhile engages in the construction of several gigafabs for battery cell production. The clients are vehicle manufacturers, battery manufacturers and energy companies. Exyte board member and CEO of Exyte's business segment Advanced Technology Facility Garvey says: "With our expertise in this growth market, we are making a significant contribution to the climate-friendly mobility of tomorrow." Biopharma & Life Sciences: Contributing to the fight against common diseases Sales of Biopharma & Life Sciences reached €579 million in 2023 (2022: €610 million). The order intake grew by 12% to €650 million (2022: €581 million). The segment, accounting for 8.2% of Exyte's total sales in 2023, is benefitting from major investments of global pharmaceutical companies, especially in Asia and Europe. Exyte, for example, is working for leading providers of novel diabetes medications that can also be used to treat other diseases. Thus, the company is making a significant contribution towards fighting widespread diseases of diabetes and obesity. In the US, Exyte has been awarded a renovation project by a leading biotechnology company. Moreover, Exyte successfully completed a mRNA vaccine fast-track production facility in Asia. It took only 13 months from the design phase to the operational qualification and handover. Data Centers: Enabler of artificial intelligence The Data Centers business segment benefits from the increasing volume of data, driven, for example, by applications of artificial intelligence. Sales in the Data Centers segment reached €414 million, an increase of 44% (2022: €288 million), while the order intake rose by 13% to €469 million (2022: €415 million). In 2023, the Data Centers business was driven by projects for blue-chip software and technology companies in Europe and South-East Asia. To accelerate the growth of the company's Data Centers business segment and to meet 2027 sales targets, Exyte has decided to also enter the US data center market. "The data center industry in the US is experiencing rapid growth, with increasing demand for reliable and scalable infrastructure to support digital transformation. Exyte can offer its clients innovative solutions for sustainable and high-performance data centers," Büchele explains. Technology & Services: Rising demand for products and services Technology & Services consists of entities that provide cleanroom technology, installation services, and critical equipment for subsystems to its clients as well as off-site manufacturing (OSM). In 2023 sales increased to €963 million (2022: €775 million), and the order intake reached €967 million (2022: €1.1 billion). Key Figures 2023 at a glance *by December 31, 2023 About Exyte Exyte is a global leader in the design, engineering, and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest standards in safety and quality to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life. In 2023, the company generated sales of €7.1 billion with around 9,900 employees worldwide. Contact Samy Abdel Aal Public Relations Manager Mobil: +49 172 840 33 01 [email protected] [1] The figures presented here differ from the IFRS consolidated financial statements of Exyte Holding GmbH for the 2023 fiscal year presented in the Annual Report, as these consolidated financial statements only reflect the operating business activities of the Exyte GmbH Group for the nine-month period April to December 2023, following the contribution made with effect from March 30, 2023. The figures presented in this press release are 12-month figures for the Exyte GmbH Group in its previous structure, in order to enable comparability with the previous year. Photo - SOURCE Exyte

疫苗并购财报

2024-02-07

·PRNewswire

American Academy of Hospice and Palliative Medicine Released Annual Presidential Citations

Three annual honors announced ahead of Annual Assembly meeting on Mar. 23-25 CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Today The American Academy of Hospice and Palliative Medicine (AAHPM) is announcing their three Presidential Citations of 2024 to be presented at Annual Assembly taking place from March 23 – 25 in Phoenix, Arizona. Presidential citations acknowledge individuals or groups who have made significant contributions to the field of hospice and palliative care but do not qualify for consideration in other award categories. "Presidential Citations recognize people and organizations who have raised public awareness and had an important impact on the hospice and palliative care field," said AAHPM Board President, Dr. Holly Yang. I am grateful for the significant contributions of each of the awardees and congratulate them wholeheartedly. The Carter Family is one of the recipients of a Presidential Citation, and James Earl Carter IV, grandson of President Jimmy Carter and First Lady Rosalynn Carter, will be in attendance to accept the award and represent their family. The Carter Family has inspired many in the field by raising public awareness by being open about the decision to access hospice care for both President Carter and the late Mrs. Carter. This openness has given the American public the opportunity to better understand the benefits of high-quality hospice care for patients, and their families, nearing end of life. The Hospice Medical Director Certification Board (HMDCB) is also a 2024 Presidential Citation awardee for its important work in certifying hospice physicians. David Wensel, DO FAAHPM HDMC, President of Tru Community Care will be accepting this honor on behalf of HMDCB. HMDCB was established as an independent, non-profit certifying body for hospice medical directors and other hospice physicians. Since its inception in 2012, there has been a clear need for physicians engaged in hospice care to demonstrate that they have the requisite knowledge to care for seriously ill people and their families, whether or not they decide to pursue fellowship training. Since its founding, HMDCB has certified hospice physicians in all 50 states, the District of Columbia, and Puerto Rico. The third recipient of a 2024 Presidential Citation is the International Association of Hospice and Palliative Care (IAHPC). On site accepting this honor on behalf of IAHPC will be Debra Pledger Fonte. The mission of IAHPC is to serve as a global platform to inspire, inform and empower individuals, governments, and organizations to increase access and optimize the practice of palliative care; and its vision is a world free from health-related suffering. IAHPC has been a remarkable resource for the global hospice and palliative care community, providing international advocacy, education, research and dissemination of information. IAHPC continues to be a critical organization for growing access to hospice and palliative care throughout the world, especially in low and middle income countries. For more information on the 2024 Presidential Citations and 2024 annual awards, please visit . About American Academy of Hospice and Palliative Medicine The American Academy of Hospice and Palliative Medicine (AAHPM) is the professional organization for physicians specializing in hospice and palliative medicine (HPM), as well as nurses, social workers, and other health and spiritual care practitioners committed to improving quality of life for seriously ill patients and their families. For more than 30 years, AAHPM has been dedicated to expanding access to high quality palliative care, and advancing the discipline of HPM, through professional education and training, development of a specialist workforce, support for clinical practice standards, research and public policy. AAHPM is governed by a 20-member Board of Directors and managed by a full-time staff along with additional support provided by Association Management Center (AMC) based in Chicago, IL. SOURCE American Academy of Hospice and Palliative Medicine

2024-01-30

·PRNewswire

AccentCare Names Dr. Balu Natarajan as Chief Medical Officer

Dr. Natarajan is a proven executive with extensive clinical and leadership experience in the post-acute health care space DALLAS, Jan. 30, 2024 /PRNewswire/ -- AccentCare ("the Company"), a nationally recognized leader and trusted guide in post-acute health care, announced the promotion of Balu Natarajan, M.D., to Executive Vice President and Chief Medical Officer, effective immediately. Continue Reading AccentCare Chief Medical Officer Dr. Balu Natarajan "In his almost two decades with our company, Dr. Natarajan has been an invaluable asset to our team, demonstrating exceptional leadership and medical expertise," said Laura Tortorella, AccentCare's Chief Executive Officer. "With his proven track record of putting patients first and building best-in-class clinical teams, I am confident that Dr. Natarajan will continue to advance our delivery of high-quality, consistent, and connected care." With his expanded remit, Dr. Natarajan will report directly to Tortorella and join the Company's executive leadership team. As Chief Medical Officer, he will drive AccentCare forward toward its goal of delivering understanding, empathetic, and excellent post-acute health care services across the country. In addition to overseeing Hospice and Palliative Care, Dr. Natarajan will now be responsible for supporting all of AccentCare's clinical care operations and patient experience initiatives across all areas of care nationwide. Since 2005, he has served as Chief Medical Officer – Hospice, for AccentCare (legacy Seasons Hospice & Palliative Care). "Our team will continue to be guided by the patient's voice and put patients at the center of everything we do as we deliver high-quality care. From coast to coast, patients and their families are counting on providers to help them navigate a complex health care system. I look forward to working with our clinical teams and partners to develop and implement strategies that promote innovation and drive successful patient experiences and outcomes. I am excited about working with Laura and the entire team as we continue to treat our patients with integrity, compassion, and excellence," said Dr. Natarajan. Board-certified in internal medicine, hospice and palliative care, and sports medicine, Dr. Natarajan has lectured across the United States and around the world, including at the annual meetings of the American Academy of Hospice and Palliative Medicine, American College of Physicians, and National Hospice and Palliative Care Organization (NHPCO). In 2022, he served on the board of directors for the NHPCO. Dr. Natarajan is a faculty member at Northwestern University Medical School and Midwestern University Medical School. Additionally, he serves as a mentor for several university programs with a focus on women's leadership as well as palliative care. About AccentCare® AccentCare is a nationwide leader and trusted guide in post-acute health care covering a broad continuum of services from personal care services, home health, and hospice. Our innovative care models and strategic relationships with major health systems, physician groups, insurers, and value-based providers give us a full understanding of how to deliver the best possible experience for patients and their families. Because of these distinct advantages, we can relentlessly reimagine and advance the standards of care in our communities. Headquartered in Dallas, AccentCare and our regional partners, have over 30,000 highly trained and compassionate professionals in more than 250 locations, across 31 states, and the District of Columbia, serving more than 200,000 individuals each year. Visit us at SOURCE AccentCare